

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 31/195</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/58641</b>
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: <b>PCT/US98/13107</b> (22) International Filing Date: <b>24 June 1998 (24.06.98)</b>  (30) Priority Data: 60/050,736 25 June 1997 (25.06.97) US 60/084,183 4 May 1998 (04.05.98) US  (71) Applicants (for all designated States except US): <b>WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).</b>  (72) Inventors; and (75) Inventors/Applicants (for US only): <b>SCHRIER, Denis [US/US]; 5904 Shagbark Drive, Ann Arbor, MI 48108 (US). TAYLOR, Charles, Price, Jr. [US/US]; 7560 Lake Shore Drive, Chelsea, MI 48118 (US). WEST-LUND-HIGH, Karin, Nanette [US/US]; 2004 Crescent Shore Drive, League City, TX 77573 (US).</b>  (74) Agents: <b>RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</b>			(81) Designated States: <b>AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: <b>USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES</b>			
(57) Abstract  GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Use of Gaba analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases

This invention was made in part with United States Government support under Grant No. IR01NS32778-01A1 administered by the National Institute of Health. The Federal Government may own certain rights in the invention.

5

## FIELD OF THE INVENTION

This invention relates to a method for treating inflammatory diseases by administering a gamma-aminobutyric acid (GABA) analog.

## BACKGROUND OF THE INVENTION

10 Inflammatory diseases are characterized by a complex series of histological events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocytic migration into the inflammatory focus. Many forms of inflammation are localized protective responses elicited by injury or destruction of tissues, which serves to destroy, dilute, or wall off both the injurious agent and the injured  
15 tissue. The inflammatory response itself is also responsible for pathologic tissue damage. Arthritis is a particularly devastating inflammatory disease, generally affecting older people, and is characterized by the inflammatory lesions being primarily confined to articular joints. The disease is marked by pain, heat, redness, swelling, and tissue destruction. Rheumatoid arthritis is a chronic systemic disease  
20 of the joints, marked by inflammatory changes in the synovial tissue and articular structures, and by atrophy and rarefaction of the bones. This form of inflammatory disease generally progresses to deformity and ankylosis.

Numerous anti-inflammatory treatments are known and commonly used. The most common are the nonsteroidal anti-inflammatory agents such as  
25 naproxen, diflunisal, mefenamic acid, and ketorolac tromethamine. These agents generally are used to treat short term mild inflammation and pain. More severe

-2-


inflammatory disease, such as arthritis, are treated with steroidal hormones and glucocorticoids, for example prednisolone, hydrocortisone acetate, and betamethasone sodium phosphate.

Because many of the anti-inflammatory agents are only short acting, and often produce severe side effects, the need for new therapies continue. We have now discovered that compounds which are analogs of gamma aminobutyric acid (GABA) are useful to treat inflammatory diseases. All that is required to prevent or treat the inflammatory disease according to this invention is to administer to a subject in need of treatment an anti-inflammatory amount of a GABA analog.

Several GABA analogs are known. Gabapentin, a cyclic GABA analog, is now commercially available and extensively used clinically for treatment of epilepsy and neuropathic pain. Such compounds are described in U.S. Patent 4,024,175. Another series of GABA analogs is described in U.S. Patent 5,563,175.

## SUMMARY OF THE INVENTION

This invention provides a method for preventing and treating inflammatory diseases comprising administering to a subject suffering from such disease or suspected of developing such disease and in need of treatment an effective amount of a GABA analog. A preferred embodiment utilizes a cyclic amino acid compound of Formula I




I

wherein  $\text{R}_1$  is hydrogen or lower alkyl and  $n$  is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof. An especially preferred embodiment utilizes a compound of Formula I where  $\text{R}_1$  is hydrogen and  $n$  is 5, which compound is 1-(aminomethyl)-cyclohexane acetic acid, known generically as

-3-

gabapentin. Other preferred GABA analogs have Formula I wherein the cyclic ring is substituted, for example with alkyl such as methyl or ethyl. Typical of such compounds include (1-aminomethyl-3-methylcyclohexyl) acetic acid, (1-aminomethyl-3-methylcyclopentyl) acetic acid, and (1-aminomethyl-3,4-dimethylcyclopentyl) acetic acid.

In another embodiment, the anti-inflammatory method of the invention utilizes a GABA analog of Formula II



II

or a pharmaceutically acceptable salt thereof, wherein

- 10  $\text{R}_1$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;  
 $\text{R}_2$  is hydrogen or methyl; and  
 $\text{R}_3$  is hydrogen, methyl, or carboxyl.

- 15 Diastereomers and enantiomers of compounds of Formula II can be utilized in the invention.

An especially preferred method of the invention employs a compound where  $\text{R}_2$  and  $\text{R}_3$  are both hydrogen, and  $\text{R}_1$  is  $-(\text{CH}_2)_{0-2}$ -i  $\text{C}_4\text{H}_9$  as an (R), (S), or (R,S) isomer.

- 20 A more preferred embodiment of the invention utilizes 3-aminomethyl-5-methyl-hexanoic acid, and especially (S)-3-(aminomethyl)-5-methylhexanoic acid, now known generically as pregabalin. Pregabalin is also known as "CI-1008" and "S-(+)-3-IBG." Another preferred compound of Formula II is 3-(1-aminoethyl)-5-methylhepanoic acid.

## DETAILED DESCRIPTION OF THE INVENTION

As noted above, the method of this invention utilizes any GABA analog. A GABA analog is any compound derived from or based upon gamma-aminobutyric acid, and causes an anti-inflammatory effect in accordance with this invention.

5 The compounds are readily available, either commercially, or by synthetic methodology well-known to those skilled in the art of organic chemistry. The preferred GABA analogs to be utilized in the method of this invention are cyclic amino acids of Formula I. These are described in U.S. Patent 4,024,175 which is incorporated herein by reference. Another preferred method utilizes the GABA  
10 analogs of Formula II, and these are described in U.S. Patent 5,563,175 which is incorporated herein by reference.

All that is required to practice the anti-inflammatory method of this invention is to administer a GABA analog in an amount that is effective to prevent or treat the inflammatory condition. Such anti-inflammatory amount will generally  
15 be from about 1 to about 300 mg per kg of subject body weight. Typical doses will be from about 10 to about 5000 mg per day for an adult subject of normal weight.

Pharmaceutical compositions of a GABA analog or its salts are produced by formulating the active compound in dosage unit form with a pharmaceutical carrier. Some examples of dosage unit forms are tablets, capsules, pills, powders,  
20 aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses. Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and  
25 potato starch, cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar; alginate acid; isotonic saline, and phosphate  
30 buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations. The compositions to be employed in the invention

-5-

can also contain other components such as coloring agents, flavoring agents, and/or preservatives. These materials, if present, are usually used in relatively small amounts. The compositions can, if desired, also contain other therapeutic agents commonly employed to treat inflammation, for example, aspirin, naprosyn, and similar anti-inflammatory agents.

The percentage of the active ingredients in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active ingredient is present, for example, up to about 95%.

Routes of administration of the GABA analog or its salts are oral or parenteral. For example, a useful intravenous dose is between 5 and 50 mg, and a useful oral dosage is between 20 and 800 mg. The dosage is within the dosing range used in treatment of inflammatory diseases such as arthritis, or as would be determined by the needs of the patient as described by the physician.

A unit dosage form of the GABA analog to be used in this invention may also comprise other compounds useful in the therapy of inflammatory diseases.

The advantages of using the compounds of Formula I and II, especially gabapentin and pregabalin, in the instant invention include the relatively nontoxic nature of the compounds, the ease of preparation, the fact that the compounds are well-tolerated, and the ease of IV and oral administration of the drugs. Further, the drugs are not metabolized in the body.

The subjects as used herein are mammals, including humans.

The ability of GABA analogs to treat inflammatory diseases according to this invention has been established in several animal models of inflammation and arthritis.

## BRIEF DESCRIPTION OF FIGURES

Figure 1 shows the effects of pregabalin (designated as S-(+)-3-IBG), its corresponding R optical enantiomer R-(-)-3-isobutyl GABA (designated as R-(-)-3-IBG), and aCSF (artificial cerebrospinal fluid) on thermal PWL (paw withdrawal latency), on circumference of the knee joint, and on degree of pain in animals prior to development of acute arthritis.

Figure 2 shows the effects of 0.9 and 10 mg/mL doses of pregabalin, R-(-)-3-IBG, and aCSF on thermal paw withdrawal latencies, administered after development of acute arthritis.

Figure 3 shows the effects of 0.9 and 10 mg/mL of Pregabalin, R-(-)-3-IBG and aCSF on joint swelling, administered after development of acute arthritis.

Figure 4 shows the effects of 0.9 and 10 mg/mL of pregabalin, R-(-)-3-IBG and aCSF on pain-related behavior, when administered after development of acute arthritis.

The following detailed examples illustrate the specific anti-inflammatory activity of GABA analogs.

## EXAMPLE 1

Gabapentin was evaluated in a streptococcal cell wall (SCW)-induced paw edema model. Female Lewis rats were sensitized to SCW (6 µg/rat) in the right tibiotalar joint on Day 0. Vehicle (0.5% hydroxypropylmethylcellulose/0.2% Tween 80) or drug (100 mg/kg, BID) was administered orally (10 mL/kg) beginning 1 hour before initiation of the delayed-type hypersensitivity reaction by systemic SCW (100 µg/rat) on Day 21, and given through Day 24. Assessment of hindpaw edema was determined on Days 22 through 25 by mercury plethysmometry.

Gabapentin was found to significantly inhibit swelling on Days 22, 23, 24, and 25 (58%, 77%, 83%, and 81%, respectively).

## EXAMPLE 2



-7-

Pregabalin was evaluated in a similar assay and showed dramatic anti-inflammatory activity. The assay is a streptococcal cell wall (SCW) induced reactivation arthritis assay. Female Lewis rats were injected intra-articularly with 10  $\mu$ L of 100 p fraction peptidoglycan polysaccharide (PG-PS) suspended in phosphate buffered saline (PBS). The contralateral joints were injected with PBS as control. Systemic challenge with 100  $\mu$ g of PG-PS was given via the tail vein 21 days after the initial inoculation. The animals were dosed orally three times a day with pregabalin (3, 10, and 30 mg/kg) on a 12-hour cycle for 72 hours. The first dose was given 1 hour before the systemic challenge.

Systemic challenge on Day 21 of previously sensitized animals with SCW resulted in acute swelling in the sensitized ankle. The volume of the ankles increased by about 0.5 mL within 72 hours. Pregabalin at 10 and 30 mg/kg dose dependently attenuated the increase in edema up to 40% during the 72-hour observation period. The results are present in Table 1.

TABLE 1

Effect of Pregabalin on Ankle Swelling  
(Days 0-20 were sensitization period)

	Day 21 PG-PS Challenge	Day 22	Day 23	Day 24	
Swelling (delta edema, mL)	0	0.20	0.45	0.50	0 (n = 6)
	0	0.12	0.38	0.50	3.0 (n = 6)
	0	0.04	0.25	0.31	10.0 (n = 4)
	0	0.06	0.20	0.21	30.0 (n = 6)
					Pregabalin oral (mg/kg)

The foregoing assay establishes that GABA analogs such as gabapentin and pregabalin are effective anti-inflammatory agents and cause a reduction in swelling of the type encountered in patients suffering from arthritis.

### EXAMPLE 3

5           Pregabalin (which is an S-isomer, and is also known as CI-1008, and as S-(+)-3-IBG) was also evaluated in the following anti-inflammatory test, along with the corresponding R-isomer, (R)-3-(aminomethyl)-5-methyl-hexanoic acid (also referred to as R-(-)-3-IBG). Acute experimental arthritis was induced in rats by injection of kaolin and carrageenan into the knee joint. The inflammatory  
10           agent, carrageenan, causes plasma extravasation and edema following the release of neuropeptides and other inflammatory mediators into the joint cavity. Concomitant with the injury to the joint tissue, both peripheral and central sensitization occurs, which is manifested in the awake rat as hyperalgesia, which can be easily quantified by measuring a reduction in paw withdrawal latencies to a  
15           radiant heat source. Both pregabalin and its R-stereoisomer (R-(-)-3-IBG) were administered before inflammation was induced, and after the inflammation was developed.

          Thirty-six male Sprague-Dawley rats (235-380 g) were anesthetized with sodium pentobarbital (Nembutal; 50 mg/kg<sup>-1</sup> i.p.). A microdialysis fiber  
20           (200 µm o.d., 45000 MW Cut-off, Hospal AN69) was coated with epoxy resin, except for a 2 mm section. A small midline incision was made in the back at the level of the last rib. The muscle was then removed from around the T<sub>12</sub> vertebra and a hole drilled in both lateral aspects. The microdialysis fiber was then passed transversely through the dorsal horn of the spinal cord between lumbar segments  
25           L<sub>4</sub>-L<sub>6</sub> so that the permeable 2 mm of the fiber lay in the dorsal horn. The microdialysis fiber was connected to PE<sub>20</sub> tubing (Becton and Dickson) which was then tunneled under the skin to the nape of the neck. The fiber was stabilized with dental cement. Artificial cerebrospinal fluid (aCSF) was pumped through the

-9-

tubing at a rate of 5  $\mu$ L/min for 1 hour before the PE<sub>20</sub> was sealed and the animals allowed to recover.

As a measure of thermal hyperalgesia, animals were tested for paw withdrawal to radiant heat. On the day following fiber placement, animals were housed in small lucite cubicles on an elevated glass plate. Radiant heat was applied to the plantar surface of the heel of the hindpaw until the rat lifted the paw. The time at which this occurred was considered the paw withdrawal latency (PWL). Both paws were tested independently at 5-minute intervals, for a total of 5 trials. A mean of these five readings was used as the PWL. In pre-treatment rats, PWL was measured before administration of any GABA analogs (baseline) and after the GABA analog had been infused for 1.5 hours, at which time kaolin and carrageenan was injected into the knee joint. PWL was measured for a final time 4 hours after arthritis induction. In the post-treatment group, the animals were tested before induction of arthritis in the knee joint (control), 4-hours post-induction, and 1.5 hours after of drug infusion, i.e. 5.5 hours after arthritis induction. A decrease in the PWL to radiant heat in an animal with knee joint inflammation is indicative of secondary hyperalgesia.

The circumference of the knee joint was also measured before injection of kaolin and carrageenan (control) using a flexible tape measure. The extent of guarding of the hindpaw was also noted after arthritis was induced. To quantify these changes, the animals were graded by a subjective pain rating scale (0-5), where: 0 is normal; 1 is curling of the toes; 2 is eversion of the paw; 3 is partial weight bearing; 4 is non-weight bearing and guarding; and 5 is avoidance of any contact with the hindlimb.

### Induction of Arthritis

Rats were anesthetized briefly with sodium methohexital (Brevital; 60 mg/kg<sup>-1</sup> i.p.) after the control behavioral test (post-treatment group) or after infusion of the drug (pre-treatment group). The knee joint was then injected with 3% kaolin and 3% carrageenan suspended in sterile saline (0.1 mL; pH 7.4). The knee joint was then flexed manually until the rat awoke (approximately 5 minutes).

-10-

### Administration of GABA Analogs

All GABA analogs were dissolved in an artificial cerebral spinal fluid solution (aCSF) (pH 7.4, adjusted by bubbling with 95% CO<sub>2</sub>/5% O<sub>2</sub>) and infused through the spinal cord at 5  $\mu$ L/min<sup>-1</sup>. The animals received either pregabalin, R-(-)-3-IBG, or aCSF. In the post-treatment group, the GABA analogs were infused at concentrations of 0.1, 0.9, and 10 mg/mL. In contrast, the pre-treatment group received a single dose of 10 mg/mL.

### Statistical Analysis

The data was normally distributed. Statistical analyses were carried out using unpaired t-tests for comparison of differences between treatment groups at the same timepoint. Paired t-tests were used to compare before and after treatment within the same group. A P value of less than 0.05 was used to indicate significance. Data are expressed as means  $\pm$  s.e.m. Tests were carried out using Statistica (Jandel Corporation).

## Results

### Effect of Pregabalin and its R-Isomer Infused Into the Spinal Cord Before the Development of Acute Arthritis

Infusion of 10 mg/mL of pregabalin, its R-isomer, or aCSF into the dorsal horn of the spinal cord alone did not change PWL in the thermal hyperalgesia test when compared to baseline values. The PWL of the rats treated with aCSF before the induction of inflammation was significantly reduced at 4 hours after injection of kaolin and carrageenan ( $P < 0.01$ , paired t-test), when compared to the value recorded immediately before injection. There was also a significant difference ( $P < 0.05$ , unpaired t-test) between the injected limb and the uninjected limb at this time.

However, in the rats infused with a concentration of 10 mg/mL pregabalin or its R-isomer through the spinal cord for 1.5 hours before the injection of kaolin and carrageenan into the knee joint, no secondary thermal hyperalgesia was observed 4-hours post-injection (Figure 1, top panel). No significant difference

-11-

was observed between the PWL value recorded 4 hours after inflammation and that recorded prior to injection of kaolin and carrageenan, nor between the inflamed limb and the uninflamed limb 4 hours after injection of kaolin and carrageenan.

5            Infusion of pregabalin or its R-isomer into the spinal cord for 1.5 hours before the induction of arthritis also significantly reduced ( $P < 0.05$ ; unpaired t-test) the amount of swelling typical after injection of kaolin and carrageenan into the knee joint by approximately 30%, when compared to rats in which aCSF was infused (Figure 1, middle panel). Further, pre-treatment with pregabalin or its  
10        R-isomer prevented the development of abnormal paw posture indicative of spontaneous pain (Figure 1, bottom panel).

#### **Effect of Pregabalin and its R-isomer Infused Into the Spinal Cord After the Development of Acute Arthritis**

15            Four hours after the induction of acute inflammation of the knee joint, there was a decrease in the PWL to radiant heat of the ipsilateral footpad, when compared to the control value, in all animals tested ( $n = 30$ ), indicating the presence of secondary hyperalgesia (Figure 2). This decrease was significant (paired t-test,  $p < 0.01$ ). Four hours after inflammation of the knee joint, there was a significant increase in knee joint circumference compared to the measurement  
20        recorded immediately before injection of kaolin and carrageenan ( $P < 0.05$ , paired t-test; Figure 3). After inflammation, there was also a change in the rats' posture (decreased weight bearing upon the swollen limb, and curling of the toes) reflected by the increased spontaneous pain rating score given to the rats (Figure 4, hollow bars).

25            The infusion of 0.9 mg/mL pregabalin or its R-isomer into the dorsal horn of the spinal cord reduced the thermal hyperalgesia at 5.5 hours (Figure 2, upper panel). Although the PWL recorded after infusion of either drug was significantly different from that recorded 4 hours after inflammation, it was still significantly less than the control value. Pregabalin was more effective in reducing thermal  
30        hyperalgesia than its R-isomer. Infusion of a higher dose, 10 mg/mL, of pregabalin or its R-isomer, after inflammation of the knee joint, resulted in a return of the

-12-

PWL to the control value (Figure 2, lower panel). In contrast, infusion of aCSF into the dorsal horn did not reduce the thermal hyperalgesia; the PWL at 4 hours after inflammation and after aCSF infusion were not significantly different.

5 The spontaneous pain was also reduced by infusion of both doses of pregabalin and its R-isomer. After infusion of either isomer of the drug, the paw posture was almost normal, whereas after infusion of aCSF, curling of the toes and eversion of the paw were observed.

10 The results from these studies show that injection of kaolin and carrageenan into the knee joint of the rat results in an acute arthritis which is characterized by secondary thermal hyperalgesia, swelling of the knee joint, and spontaneous pain. Infusion of pregabalin and R-(-)-3-IBG into the dorsal horn of the spinal cord for 1.5 hours before the injection of kaolin and carrageenan reduced the amount of swelling observed, and blocked the secondary hyperalgesia and spontaneous pain. The GABA analogs are thus useful to treat inflammatory  
15 diseases, especially arthritis.

#### EXAMPLE 4

Gabapentin, another GABA analog, was evaluated in a similar assay and shown to be effective in both preventing and reversing the affects of kaolin/carrageenan knee joint inflammation, secondary heat hyperalgesia and  
20 spontaneous pain-related behaviors.

#### Methods

25 Thirty animals in two experimental groups were treated (1) prior to, and (2) after induction of experimental arthritis. Inflammation was induced within the knee joint by injection of kaolin/carrageenan. Gabapentin or aCSF was administered through a microdialysis fiber positioned in the dorsal-horn for spinal treatment, or subcutaneously in the nape of the neck for systemic release. All experiments were carried out by an observer blind to the drug treatment.

**Placement of microdialysis fibers.** Sprague-Dawley rats (220-270 g) were anesthetized with sodium pentobarbital (nembutal, 50 mg/kg, i.p.). A

-13-

microdialysis fiber (200  $\mu\text{m}$  o.d., 45000 MW Cut-off, Hospal AN69) was coated with epoxy resin, except for a 2 mm section. In 24 animals, the microdialysis fiber was placed in the dorsal horn. A small midline incision was made in the skin over the L<sub>1</sub> vertebral level. The L<sub>1</sub> vertebra was cleared of muscle and a hole drilled in both sides of the lamina. The microdialysis fiber was then passed through the holes in the vertebrae and transversely through the dorsal horn of the spinal cord. The microdialysis fiber lay between L<sub>4</sub>-L<sub>6</sub> segments with the permeable 2 mm of the fiber in the dorsal horn. The microdialysis fiber was connected to PE<sub>20</sub> tubing (Becton Dickinson) which was tunneled under the skin to the nape of the neck.

The connecting joint between the microdialysis fiber and PE<sub>20</sub> tubing was stabilized with dental cement. The aCSF was pumped through the tubing at a rate of 5  $\mu\text{L}/\text{min}$  for 1 hour before the PE<sub>20</sub> tubing was sealed, and the animal was allowed to recover for 24 hours. Once the rats were awake, they were examined for motor deficits; any rat which had motor deficits was excluded from the study. As a systemic control for drug administration in another 6 rats, the microdialysis fiber was implanted in the subcutaneous tissue at the nape of the neck.

**Behavior testing and assessment of arthritis.** The PWL to noxious radiant heat was tested as a measure of thermal hyperalgesia. A decrease in the PWL in animals with knee joint inflammation was interpreted as indicative of secondary hyperalgesia. Since the radiant heat stimulus is applied to the plantar surface of the hindpaw at quite some distance from the inflamed knee joint, the measure reported represents secondary heat hyperalgesia.

On the day following fiber placement, animals were housed in small lucite cubicles on an elevated glass plate. Radiant heat was applied to the plantar surface of the hindpaw until the rat lifted the paw. The time at which this occurred was considered the PWL. Both paws were tested independently at 5-minute intervals for a total of five trials. A mean of these five readings was used as the PWL for each time points. In pretreatment rats ( $n = 12$ ), PWL was measured before administration of any drugs (baseline), after the drug had been infused for 1.5 hours (post-drug), and 4 hours after arthritis. In the post-treatment group

-14-

(n = 18), the animals were tested before induction of arthritis in the knee joint (baseline), 4 hours after induction of arthritis, and 1.5 hours after drug infusion, i.e., 5.5 hours after arthritis induction.

5 The pain-related behavior, the extent of guarding of the hindpaw of the arthritis limb, was scored by two independent observers. To quantify these changes, the animals were graded by a subjective pain rating scale (0-5) where: 0 is normal, 1 is curling of the toes, 2 is eversion of the paw, 3 is partial weight bearing, 4 is non-weight bearing and guarding, and 5 is avoidance of any contact with the hindpaw.

10 The circumference of the knee joint was also measured using a flexible tape measure before induction of arthritis (baseline), 4 hours after induction of arthritis (pretreatment and posttreatment group), and 1.5 hours after drug infusion in the posttreatment group (5.5 hours after induction of arthritis).

15 **Induction of arthritis.** Rats were anesthetized briefly with methohexital sodium (Brevital sodium, 60 mg/kg i.p.) after baseline behavior test (post-treatment group) or after infusion of the drug (pre-treatment group). The knee joint was then injected with 0.1 mL of 3% kaolin and 3% carrageenan suspended in sterile saline, and was flexed manually until the rat awoke (approx. 5-10 min.).

20 **Administration of drug.** The animal received either gabapentin or aCSF as a control. The gabapentin was dissolved in aCSF. Both gabapentin and aCSF were infused through the microdialysis fiber at a rate of 5  $\mu$ L/minute. The pH of the gabapentin solution and aCSF were adjusted by bubbling with 95% CO<sub>2</sub>/5% O<sub>2</sub> (about 7.4) before using.

The single dose of 10 mg/mL of gabapentin was used for the study.



-15-

**Statistical analysis.** The results for each group were expressed as the average percent change from baseline  $\pm$  the standard error of the mean (s.e.m.). Paired t-tests were used to compare each animal's test responses to its own baseline ( $P < 0.01$ ).

## 5      **Results**

**Baseline measures.** The baseline PWL, spontaneous behavior, and knee joint circumference of all rats used in these studies were measured prior to infusion of the drug or vehicle through the spinal cord or subcutaneously (Table 2). The mean PWL and knee joint circumference were  $10.52 \pm 0.39$  sec and  $5.26 \pm 0.03$  cm, respectively. No spontaneous pain-related behaviors were noted and a score of zero given.

10

**Consequent changes with joint inflammation.** In Table 2, the expected outcome in arthritic animals for all measures is presented. The data includes the combined measures for the aCSF arthritic control animals from both treatment groups. In the aCSF-treated arthritic control rats ( $n = 12$ ), 4 hours after injection of kaolin and carrageenan, the PWL to noxious radiant heat decreased to 76% of baseline value. This decrease was significant (paired t-test,  $p < 0.01$ ) and indicated the presence of secondary hyperalgesia.

15

20

In arthritic animals, there was a significant change in the hindpaw posture of the rat, indicative of spontaneous ongoing pain-related behavior. These postural changes, representing spontaneous ongoing pain-related behavior, were represented by a score of  $1.25 \pm 0.13$  ( $p < 0.01$ ). A significant 14% increase in knee joint circumference is noted compared to the baseline (paired t-test,  $p < 0.01$ ).

-16-

TABLE 2  
Non-arthritic Vs. Arthritic Animals

	PWL (sec.)	PWL (% of baseline)	Behavior Score	Circumference (cm)	Circumference (% of baseline)
Baseline	11.47 ± 0.56	100	0	5.18 ± 0.04	100
Arthritis (4 h)	8.66 ± 0.56*	76.42 ± 3.10*	1.25 ± 0.13*	5.92 ± 0.09*	114.38 ± 1.86*

\* p &lt; 0.01.

**The effect of gabapentin infusion directly into the spinal cord before knee joint inflammation.** Gabapentin was effective in preventing the development of secondary hyperalgesia responses to the applied radiant heat. Gabapentin or aCSF were infused through the microdialysis fiber into the spinal cord before the knee joint was injected with kaolin and carrageenan. After 1.5 hours of spinal drug infusion, there were no significant changes of the PWL to the radiant heat compared to the baseline (Table 3). Four hours after injection of the knee joint with kaolin and carrageenan, the PWL response to radiant heat and the posture of the hindpaw with arthritis were not significantly changed from non-arthritic baseline. In contrast, the aCSF-treated animals had a significant reduction in their PWL responses, and demonstrated significant spontaneous pain-related behaviors. The circumference of the inflamed joint was increased significantly 4 hours after arthritis, similar to the aCSF arthritic control rats. Thus, gabapentin was highly effective in preventing the development of secondary heat hyperalgesia and measures of spontaneous pain-related behaviors.

TABLE 3  
Effects of Gabapentin Administered Prior to Inflammation

Groups	Baseline (% of control)	PWL (1.5 h after drug infusion)	PWL (4 h after joint injection)	Behavior Score (4 h after joint inspection)	Circumference (4 h after joint injection)
Gabapentin (n = 6)	100	105.18 ± 4.56	100.03 ± 4.37	0.67 ± 0.20	114.20 ± 1.53*
aCSF (n = 6)	100	93.12 ± 6.31	74.47 ± 3.44*	1.33 ± 0.2*	114.87 ± 1.74*

\* p &lt; 0.01.

-17-

**Effect of gabapentin infusion into the spinal cord or subcutaneously after knee joint inflammation.** Post-treatment of arthritic animals with gabapentin reversed the secondary heat hyperalgesia and spontaneous pain-related behaviors when administered spinally. Two groups of animals received gabapentin in post-treatment studies (Table 4). One group of rats was infused with the drug through a microdialysis fiber implanted directly into the spinal cord; the other group received gabapentin systemically through a microdialysis fiber implanted subcutaneously at the nape of the neck.

Four hours after injection of kaolin and carrageenan, all animals displayed reduced PWL responses and spontaneous pain-related behaviors. In the group infused with gabapentin spinally, the PWL significantly decreased to about 81% of baseline measurements (paired t-test,  $p < 0.01$ ). By 1.5 hours after spinal gabapentin infusion, the PWL measurements returned back to the baseline, and the toes became almost flat.

TABLE 4  
Effects of Gabapentin Administered After Inflammation

Groups	PWL or Circumference (% of control)	PWL (after 4 h arthritis)	PWL (after 5.5 h arthritis)	Behavior Score (after 5.5 h arthritis)	Circumference (after 5.5 h arthritis)
Gabapentin (spinal cord) (n = 6)	100	$80.71 \pm 3.23^*$	$100.85 \pm 10.63$	$0.50 \pm 0.20$	$122.22 \pm 2.32^*$
Gabapentin (subcutaneous) (n = 6)	100	$85.05 \pm 3.68^*$	$81.89 \pm 4.43^*$	$1.17 \pm 0.29^*$	$120.66 \pm 3.59^*$
aCSF (spinal cord) (n = 6)	100	$78.37 \pm 5.37^*$	$78.57 \pm 4.38^*$	$1.17 \pm 0.28^*$	$113.89 \pm 3.49^*$

\*  $p < 0.01$ .

In the group which was infused with gabapentin subcutaneously, the PWL to noxious radiant heat significantly decreased by 15% from baseline measurements 4 hours after joint injection, and after 1.5 hours drug infusion, the

-18-

PWL continued to decrease to 82% of the baseline value, similar to aCSF control arthritic rats. Both the pain-related behavior score and the circumference of the inflamed joint increased significantly after 4 hours arthritis and 1.5 hours drug infusion (5.5 h post) for all groups.

- 5           The foregoing study establishes that GABA analogs such as gabapentin are effective in both preventing and reversing the affects of kaolin/carrageenan knee joint inflammation on secondary heat hyperalgesia and spontaneous pain-related behaviors. In both treatment groups, the significant finding was the ability of gabapentin to retain (or return) the PWL latency scores to baseline. Its
- 10           effectiveness in reducing the hyperalgesia and pain-related behavior after the arthritis is fully developed in this model indicates that gabapentin and similar GABA analogs will have clinically useful effects in clinical inflammatory conditions.


-19-

## CLAIMS

What is claimed is:

1. A method for preventing and treating inflammatory diseases comprising administering to a subject in need of treatment an anti-inflammatory amount of a GABA analog.

2. A method according to Claim 1 employing a compound of Formula I




I

wherein R<sub>1</sub> is hydrogen or lower alkyl and n is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof.

3. The method according to Claim 2 employing gabapentin.
4. A method according to Claim 2 employing a compound of Formula I wherein the cyclic ring is substituted with one or two groups selected from methyl and ethyl.
5. The method according to Claim 4 employing (1-aminomethyl-3-methylcyclohexyl) acetic acid.
6. The method according to Claim 4 employing (1-aminomethyl-3-methylcyclopentyl) acetic acid.
7. The method according to Claim 4 employing (1-aminomethyl-3,4-dimethylcyclopentyl) acetic acid.

-20-

8. A method according to Claim 1 employing a compound of Formula II



II

wherein R<sub>1</sub> is a straight or branched alkyl of from 1 to 6 carbon atoms,  
phenyl, or cycloalkyl of from 3 to 6 carbon atoms;

5 R<sub>2</sub> is hydrogen or methyl; and

R<sub>3</sub> is hydrogen, methyl, or carboxyl, and the pharmaceutically acceptable  
salts thereof.


9. The method according to Claim 8 employing pregabalin.

10. The method according to Claim 8 employing R-(3)-(aminomethyl)-  
5-methyl-hexanoic acid.

11. The method according to Claim 8 employing 3-(1-aminoethyl)-5-  
methyl-hexanoic acid.


1/9

FIG-1A



2/9


FIG-1B






3/9

FIG-1C




4/9

FIG-2A



5/9



6/9

FIG-3A




FIG-3B




FIG-4A





FIG-4B



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/13107

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/195

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 8514 Derwent Publications Ltd., London, GB; Class B05, AN 85-084635 XP002082265 & JP 60 036413 A (NAGAI K) , 25 February 1985 see abstract	1
Y	see the whole document	2-11
P,X	WO 98 17627 A (BRYANS JUSTIN STEPHEN ;HORWELL DAVID CHRISTOPHER (GB); KNEEN CLARE) 30 April 1998 * p.1, l.18; claim 1 *	1
P,Y	WO 98 03167 A (SINGH LAKHBIR ;WARNER LAMBERT CO (US)) 29 January 1998 see claims 1-4	8-11
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Date of mailing of the international search report

05/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P



# INTERNATIONAL SEARCH REPORT

Int tional Application No

PCT/US 98/13107

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 024 175 A (SATZINGER GERHARD ET AL) 17 May 1977 cited in the application see claims 1-11	2-7
Y	US 5 563 175 A (SILVERMAN RICHARD B ET AL) 8 October 1996 see claim 1	8-11

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13107

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9817627 A	30-04-1998	AU 4669797 A	15-05-1998
WO 9803167 A	29-01-1998	AU 3602497 A	10-02-1998
US 4024175 A	17-05-1977	DE 2460891 A	01-07-1976
		AT 340892 B	10-01-1978
		AT 975075 A	15-05-1977
		AU 8774175 A	23-06-1977
		BE 836835 A	18-06-1976
		CA 1052811 A	17-04-1979
		CH 612665 A	15-08-1979
		CH 612666 A	15-08-1979
		CH 612664 A	15-08-1979
		DE 2543821 A	14-04-1977
		DK 581475 A,B,	22-01-1976
		FI 753613 A,B,	22-06-1976
		FR 2294697 A	16-07-1976
		GB 1465229 A	23-02-1977
		IE 42382 B	30-07-1980
		JP 941538 C	20-02-1979
		JP 51088940 A	04-08-1976
		JP 53024064 B	18-07-1978
		LU 74058 A	20-07-1976
		NL 7514900 A,B,	23-06-1976
		SE 423385 B	03-05-1982
		SE 7514442 A	22-06-1976
		US 4087544 A	02-05-1978
US 5563175 A	08-10-1996	MX 9302970 A	31-05-1994
		US 5684189 A	04-11-1997
		US 5608090 A	04-03-1997
		US 5599973 A	04-02-1997
		US 5710304 A	20-01-1998
		AU 677008 B	10-04-1997
		AU 4379493 A	13-12-1993
		CA 2134674 A	25-11-1993
		CZ 9402849 A	15-03-1995
		EP 0641330 A	08-03-1995
		FI 945426 A	18-11-1994
		HU 71522 A	28-12-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13107

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5563175 A		JP 7508288 T	14-09-1995
		NO 944370 A	21-11-1994
		NZ 253459 A	24-03-1997
		SG 48288 A	17-04-1998
		SK 139594 A	10-05-1995
		WO 9323383 A	25-11-1993
		AU 9137091 A	25-06-1992
		MX 9102241 A	31-01-1994
		WO 9209560 A	11-06-1992